北京若生智能科技有限公司
Drug Database
AT

atenolol + bendroflumethiazide (TenBen / Amoretic LD / Amoretic)

✓ Approved

Warner Chilcott PLC · ADRB1 · 小分子

什么是 atenolol + bendroflumethiazide？

atenolol + bendroflumethiazide 是一种小分子，由Warner Chilcott PLC研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名TenBen, Amoretic LD, Amoretic
公司Warner Chilcott PLC
药物类别小分子
分子靶点ADRB1, SLC12A3
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Warner Chilcott PLC

作用机制

分子靶点

atenolol + bendroflumethiazide 作用于 2 个分子靶点：

ADRB1adrenoceptor beta 1 (B1AR, RHR)
SLC12A3solute carrier family 12 member 3 (NCCT, NCC)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

atenolol + bendroflumethiazide 针对 2 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersHypertension✓ Approved
Renal and urinary disordersRenal failure✓ Approved

相关研究文献

PubMedAnalytical chemistry2026-09-03

An Analyte-Specific LC-IMS-HRMS Framework for Enhanced Identification Confidence in Target Screening of Contaminants in Complex Matrices.

Diamanti Konstantina S KS, Damalas Dimitrios E DE, Gkotsis Georgios O GO, Panagopoulou Eleni I EI et al.

Reliable identification of contaminants in complex matrices remains hampered by low-abundance signals, complex spectra, and coeluting isobars in liquid chromatography-high-resolution mass spectrometry (LC-HRMS) analyses with data-independent acquisitions. Moreover, wide-scope target screening workflows covering hundreds to thousands of known compounds from reference standards analyses often fail to fully exploit the acquired data, leading to false positives and false negatives. Herein, trapped ion mobility spectrometry (TIMS) was integrated into LC-HRMS, and an enriched database and an analyte-specific framework were introduced for enhanced identification confidence. The database including 1948 contaminants incorporated all MS and MS/MS qualifier ions together with their CCS values and mobility filtering windows, alongside the principal ion. Specific qualifiers were designated as mandatory for the first time by evaluating their relative intensity compared to the principal ion (≥50%), with the established identification points systems being refined accordingly to increase confidence. Regarding TIMS data, ∼2500 CCS values were determined, exhibiting high repeatability (RSD ≤ 0.70%) and interinstrument reproducibility (|ΔCCS|≤ 2%). Comparison with literature data across different IMS-HRMS platforms showed CCS accuracy within 2% for 89% of the ions. In matrix spiking experiments (raptor's eggs, human urine, wastewater), the cleaner mobility-filtered spectra resulted in improved selectivity for several contaminants' qualifiers, which improved detection at low concentrations, minimizing false negatives. Additionally, both differentiation based on CCS values (e.g., atenolol-practolol) and mandatory detection of predefined qualifiers (e.g., prometryn-terbutryn) decreased false positives. By incorporating the TIMS dimension and mandatory qualifiers as additional identification information, this work provides a robust framework for high-throughput environmental monitoring and human exposure assessment.

PMID 42689556
阅读全文 →
PubMedPloS one2026-09-03

Immobilized horseradish peroxidase hybrid biocatalysts for degradation of pharmaceuticals and other emerging micropollutants.

Al-Maqdi Khadega A KA, Morsi Rana R, Zhou Hao H, Abdussaitova Assina A et al.

With the increasing detection of emerging pollutants (EPs), such as pharmaceuticals, personal care products, and pesticides, in water bodies, there is a growing research priority to develop efficient methods for their degradation. In the present study, the degradation of 21 EPs from different classes was investigated using horseradish peroxidase (HRP) covalently immobilized onto two photocatalytic supports, TiO2 and ZnO. The hybrid biocatalysts (TiO2-HRP and ZnO-HRP) were used to degrade EPs with and without the presence of a redox mediator, 1-hydroxybenzotriazole (HOBT). The results revealed that not all EPs were equally degraded by HRP enzymes, with some pollutants showing complete, partial, or no degradation. For example, full degradation was achieved for MBT (100%), meloxicam (99.5%) and caffeic acid (98.6%). In contrast, prometryn and MCPA showed only partial degradation, reaching 19.2% and 20%, respectively, and no degradation was observed for fluometuron and atenolol. The addition of the model redox mediator, HOBT, improved the degradation of some pollutants, for example, lincomycin-HCl degradation increased to 36.9%, while trimethoprim degradation improved to 21.5%. Additionally, several pollutants, including roxithromycin, cimetidine, and caffeine, exhibited significantly higher degradation rates when treated with the immobilized HRP enzyme (TiO2-HRP or ZnO-HRP) compared to free HRP. For instance, roxithromycin degradation increased from 0.5% to 58.2% with ZnO-HRP, and for cimetidine, TiO₂-HRP improved degradation from 0.3% to 60.1% without HOBT and from 9.0% to 66.7% with HOBT. Molecular docking with the catalytic heme cofactor retained further suggested that degradation trends were not explained by docking score alone, but were influenced by ligand access to the distal heme pocket, molecular planarity, and contact topology near catalytic residues. Finally, an integrated HRP enzyme and chemical oxidation remediation strategy was applied to degrade two pollutants, trimethoprim and DEET. For trimethoprim, TiO2-HRP combined with H2O2 and UV achieved approximately 30% degradation, while for DEET, both TiO2-HRP + H2O2 + UV and ZnO-HRP + H2O2 + UV resulted in around 40% degradation, thereby highlighting a novel application for these hybrid peroxidase-photocatalysts.

PMID 42685069
阅读全文 →
PubMedPediatric cardiology2026-08-25

Recurrent Cardiac Arrest in a Pediatric Patient with Hypertrophic Cardiomyopathy and a Myocardial Bridge: Player or Spectator?

Lodeiro Carlos A CA, Boyd Chelsea C, Menillo Alexandra A, Eilers Lindsay F LF et al.

Myocardial bridge (MB) is common in patients with hypertrophic cardiomyopathy (HCM), and can reduce coronary flow leading to myocardial ischemia, fibrosis, and malignant ventricular arrhythmias resulting in sudden cardiac arrest (SCA). However, MB has not been previously reported as an isolated, modifiable cause of recurrent SCA in pediatric HCM. To describe a case of HCM with recurrent SCA found to have left anterior descending (LAD) coronary artery MB, with resolution of recurrent SCA after MB unroofing. A 13-year-old male with HCM had an epicardial implantable cardioverter defibrillator (ICD) placed after his first SCA at age 8. Atenolol was started after his second SCA at age 12. After a third SCA he was transitioned to Nadolol and Mexiletine, and underwent transvenous ICD implantation due to delayed shock secondary to under-sensing on epicardial system. He had two additional episodes of SCA, for which he was started on Amiodarone and transferred to our institution for transplant evaluation in the setting of biventricular systolic dysfunction. During transplant evaluation, exercise stress test suggested the presence of ischemia. Cardiac catheterization revealed a 6 cm proximal LAD MB, with near occlusion during systole (Figure 1). He underwent LAD unroofing and remained asymptomatic at baseline activity level with no further episodes of SCA during the subsequent follow-up. MB can cause significant compression leading to compromised coronary flow and myocardial ischemia distinct from the intrinsic underlying cardiomyopathy in HCM. Modifiable causes should be considered in cases of recurrent SCA, as treatment may alter prognostic implications.

PMID 42640473
阅读全文 →
PubMedAnalytical methods : advancing methods and applications2026-08-20

Analysis of real water samples with AQbD microextraction using thymol-based NADES: implications of uncontrolled hypertension risk in Egypt.

Elbalkiny Heba T HT, Nasry Elsaiad E, Nayer Marina M, Ahmed Sohaila S et al.

The global burden of hypertension and its severe form, resistant hypertension, affecting up to 20% of 1.4 billion adults worldwide, drives mass consumption of multiple drugs. Consequently, antihypertensive agents from different classes enter aquatic environments, yet simultaneous extraction of such chemically diverse drugs remains challenging. This work developed a green analytical method for the simultaneous determination of three model antihypertensive agents from distinct classes, namely, furosemide, atenolol, and lisinopril, in water samples. The method employed dispersive liquid-liquid microextraction using a thymol-based natural deep eutectic solvent selected for its superior hydrophobicity and tunability across varying analyte polarities and acid-base characteristics. Extraction was optimized via Box-Behnken design, followed by HPLC-UV analysis on a phenyl column with gradient elution (detection at 220 nm). The validated method showed good linearity (furosemide: 2-100 µg L-1, lisinopril: 5-100 µg L-1, and atenolol: 0.1-50 µg L-1) with LODs of 0.18, 0.66, and 0.031 µg L-1, respectively. The practical applicability of the developed method was evaluated by analyzing real water samples collected from multiple sites across Egypt. The results revealed detectable concentrations of the target pharmaceuticals in several samples, confirming the presence of these contaminants in Egyptian water systems. Specifically, furosemide was detected at 4.72 µg L-1, atenolol at 0.43 µg L-1, and lisinopril at 7.21 µg L-1 in samples collected from Giza. A comprehensive greenness assessment using the GAPI, AGREE, BAGI, and EVG tools confirmed strong alignment with sustainable chemistry principles. By enabling multi-class extraction of antihypertensive drugs with a low-ecological-footprint NADES-based protocol, this method addresses a critical gap as no prior NADES-based method exists for these three therapeutic classes together, supporting environmental monitoring and clean water objectives.

PMID 42621670
阅读全文 →
PubMedSurgery2026-08-19

Impact of chronic beta-blocker versus renin-angiotensin inhibitor use on outcomes after blunt pelvic trauma.

Dhalla Zeyanna Z, Nunn Kaitlin K, Teoh Victoria V, Arellano Diana D

Chronic cardiovascular medications, including β-blockers and renin-angiotensin system inhibitors, may modify the physiologic response to trauma. The purpose of this study is to compare outcomes of pelvic fracture patients with preinjury β-blockers versus renin-angiotensin system inhibitor use after blunt pelvic trauma. A retrospective cohort study was conducted using TriNetX. Data was collected from 2015 to 2025, with a total sample size of n = 442,947 distributed across 16 comparison groups. Propensity score matching was applied to yield equitable cohorts based on medical comorbidities. Patient groups were mutually exclusive, such that individuals were classified as taking either a β-blocker or a renin-angiotensin system inhibitor, with exclusion of patients receiving both therapies or an antiplatelet treatment. Comparisons were made with outcomes that include hemorrhage, infections, pneumonia, sepsis, deep vein thrombosis, pulmonary embolism, respiratory ventilation, and mortality. The β-blocker group demonstrated higher rates of adverse events, including hemorrhage, infections, pneumonia, sepsis, deep vein thrombosis, pulmonary embolism, respiratory ventilation, and mortality, relative to the renin-angiotensin system inhibitor group. The differences were most pronounced when renin-angiotensin system inhibitors were compared with metoprolol and labetalol, where nearly all outcomes were significantly worse in the β-blocker cohorts. In contrast, no significant differences were observed when compared with carvedilol or atenolol. Prior use of β-blockers is correlated with significantly worse rates of hemorrhage, infection, and thromboembolic events after a traumatic pelvic fracture when compared with renin-angiotensin system inhibitors. This could be due to renin-angiotensin system inhibitors attenuating the post-traumatic inflammatory response system by blocking angiotensin II, which causes inflammation, oxidative stress, endothelial dysfunction, and vasoconstriction. These findings suggest that chronic cardiovascular therapy type may influence post-pelvic trauma outcomes, underscoring the need for further investigation.

PMID 42618398
阅读全文 →
PubMedActa dermato-venereologica2026-08-13

Enalapril, Atenolol, Alendronate and DRESS Syndrome - A Case Report.

Olsson S Bertil SB, Ehinger Mats M

PMID 42593154
阅读全文 →

注册免费账户还可查看另外 8177 篇文献

免费注册查看全部文献 →

了解更多atenolol + bendroflumethiazide